 |
 |
|
|
RESÚMENES NOVIEMBRE 2005 |
Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal para acceder al
resúmen)
Social fragmentation, deprivation and urbanicity: relation to first-admission rates for psychoses
JUDITH ALLARDYCE, HARPER GILMOUR, JACQUELINE ATKINSON, TRACEY RAPSON,
JENNIFER BISHOP, R. G. McCREADI
The British Journal of Psychiatry (2005) 187: 401-406
Quantitative MRI
measures of orbitofrontal cortex in patients with chronic schizophrenia or
schizoaffective disorder
Matthew J. Hoptman,
Jan Volavka, Elisabeth M. Weiss, Pál Czobor, Philip R. Szeszko, Guido Gerig,
Miranda Chakos, Joseph Blocher, Leslie L. Citrome, Jean-Pierre Lindenmayer,
Brian Sheitman, Jeffrey A. Lieberman and Robert M. Bilder
Psychiatry Research:
Neuroimaging. Volume 140, Issue 2, 30 November 2005, Pages 133-145
Dorsolateral
prefrontal cortex morphology and short-term outcome in first-episode
schizophrenia
Konasale M.R.
Prasad, Sarah D. Sahni, Brian R. Rohm and Matcheri S. Keshavan
Psychiatry Research:
Neuroimaging. Volume 140, Issue 2, 30 November 2005, Pages 147-155
Quetiapine
has equivalent efficacy and superior tolerability to risperidone in the
treatment of schizophrenia with predominantly negative symptoms
Riedel M, Muller N,
Strassnig M, Spellmann I, Engel RR, Musil R, Dehning S, Douhet A, Schwarz MJ,
Moller HJ
Eur Arch Psychiatry Clin Neurosci. 2005 Nov 4; [Epub
ahead of print]
Diagnosis-related
regional gray matter loss over two years in first episode schizophrenia and
bipolar disorder
Farrow TF, Whitford TJ,
Williams LM, Gomes L, Harris AW
Biol Psychiatry. 2005 Nov 1;58(9):713-23. Epub 2005
Jul 5
Increased
prefrontal and hippocampal glutamate concentration in schizophrenia: evidence
from a magnetic resonance spectroscopy study
Tebartz van Elst L,
Valerius G, Buchert M, Thiel T, Rusch N, Bubl E, Hennig J, Ebert D, Olbrich HM
Biol Psychiatry. 2005 Nov 1;58(9):724-30. Epub 2005
Jul 14
Thomas Stompe,
Gerhard Ortwein-Swoboda, Kristina Ritter, Barbara Marquart and Hans Schanda
Comprehensive Psychiatry. Volume 46, Issue 6,
November-December 2005, Pages 433-439
Jyrki A. Korkeila,
Tanja Svirskis, Markus Heinimaa, Terja Ristkari, Jukka Huttunen, Tuula Ilonen,
Tom McGlashan and Raimo K.R. Salokangas
Comprehensive Psychiatry. Volume 46, Issue 6,
November-December 2005, Pages 447-452
Actions of antipsychotic drugs on pancreatic ß-cell function: contrasting effects of clozapine and haloperidol
Leonard Best, Allen P. Yates, Gavin P. Reynolds
Journal of
Psychopharmacology, Vol. 19, No. 6, 597-601 (2005)
C. Griffiths, R. J. Flanagan
Journal
of Psychopharmacology, Vol. 19, No. 6, 667-674 (2005)
Beneficial
effect of atypical antipsychotics on prefrontal brain function in acute
psychotic disorders
Ehlis AC, Zielasek J, Herrmann
MJ, Ringel T, Jacob C, Fallgatter AJ
Eur Arch Psychiatry Clin Neurosci. 2005
Oct;255(5):299-307
Rahul Manchanda,
Ross M.G. Norman, Ashok K. Malla, Rajendra Harricharan and Sandra Northcott
Schizophrenia
Research. Volume 80, Issue 1, 1 December 2005, Pages 113-116
The effect of
neuroleptic treatments on executive function and symptomatology in
schizophrenia: A 1-year follow up study
Sophie Rémillard,
Emmanuelle Pourcher and Henri Cohen
Schizophrenia
Research. Volume 80, Issue 1, 1 December 2005, Pages 99-106
Antidepressants as
add-on treatment to antipsychotics for people with schizophrenia and pronounced
negative symptoms: A systematic review of randomized trials
Christine Rummel,
Werner Kissling and Stefan Leucht
Schizophrenia
Research. Volume 80, Issue 1, 1 December 2005, Pages 85-97
Laurie McCormick,
Lawrence Decker, Peg Nopoulos, Beng-Choon Ho and Nancy Andreasen
Schizophrenia
Research. Volume 80, Issue 1, 1 December 2005, Pages 73-84
Increase in gray
matter and decrease in white matter volumes in the cortex during treatment with
atypical neuroleptics in schizophrenia
Vicente Molina,
Santiago Reig, Javier Sanz, Tomás Palomo, Carlos Benito, Javier Sánchez,
Fernando Sarramea, Javier Pascau and Manuel Desco
Schizophrenia
Research. Volume 80, Issue 1, 1 December 2005, Pages 61-71
Serum lipid
profiles and schizophrenia: Effects of conventional or atypical antipsychotic
drugs in Taiwan
Tiao-Lai Huang,
Jung-Fu Chen
Schizophrenia
Research. Volume 80, Issue 1, 1 December 2005, Pages 55-59
A comparison of
ten-year cardiac risk estimates in schizophrenia patients from the CATIE study
and matched controls
Donald C. Goff,
Lisa M. Sullivan, Joseph P. McEvoy, Jonathan M. Meyer, Henry A. Nasrallah, Gail
L. Daumit, Steven Lamberti, Ralph B. D'Agostino, Thomas S. Stroup, Sonia Davis
and Jeffrey A. Lieberman
Schizophrenia
Research. Volume 80, Issue 1, 1 December 2005, Pages 45-53
Clinical
correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE
schizophrenia trial
Del D. Miller,
Joseph P. McEvoy, Sonia M. Davis, Stanley N. Caroff, Bruce L. Saltz, Miranda H.
Chakos, Marvin S. Swartz, Richard S.E. Keefe, Robert A. Rosenheck, T. Scott
Stroup and Jeffrey A. Lieberman
Schizophrenia
Research. Volume 80, Issue 1, 1 December 2005, Pages 33-43
Prevalence of the
metabolic syndrome in patients with schizophrenia: Baseline results from the
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
schizophrenia trial and comparison with national estimates from NHANES III
Joseph P. McEvoy,
Jonathan M. Meyer, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, Lisa
Sullivan, Herbert Y. Meltzer, John Hsiao, T. Scott Stroup, Jeffrey A. Lieberman
Schizophrenia
Research. Volume 80, Issue 1, 1 December 2005, Pages 19-32
Supplementation
of vitamin C with atypical antipsychotics reduces oxidative stress and improves
the outcome of schizophrenia
Dakhale GN, Khanzode SD,
Khanzode SS, Saoji A
Psychopharmacology (Berl). 2005 Nov;182(4):494-8
Chlorpromazine
for schizophrenia: a Cochrane systematic review of 50 years of randomised
controlled trials
Clive
Elliott Adams, John Rathbone, Ben Thornley, Mike Clarke, Jo Borrill, Kristian
Wahlbeck and A George Awad
BMC Medicine 2005, 3:15; Published: 17 October 2005
Cardiovascular
disease in relation to weight in deceased persons with schizophrenia
Conley RR, Shim JC, Kelly
DL, Feldman S, Yu Y, McMahon RP
Compr Psychiatry. 2005 Nov-Dec;46(6):460-7
Efficacy of Aripiprazole Against Hostility in Schizophrenia and Schizoaffective Disorder:Data From 5 Double-Blind Studies
Jan Volavka, Pal
Czobor, Leslie Citrome, Robert D. McQuade, William H. Carson, Dusan Kostic,
Sterling Hardy, and Ronald Marcus
J Clin Psychiatry 2005;66:1362-1366
Naturalistic, Retrospective Comparison Between Second-Generation Antipsychotics and Depot Neuroleptics in Patients Affected by Schizophrenia
Livio Marchiaro,
Paola Rocca, Ferdinando LeNoci, Pierpaolo Longo, Cristiana Montemagni,
Cristiana Rigazzi, and Filippo Bogetto
J Clin Psychiatry 2005;66:1423-1431
Michael J. Sernyak,
Barbara Gulanski, and Robert Rosenheck
J Clin Psychiatry 2005;66:1463-1467
Beneficial
effect of atypical antipsychotics on prefrontal brain function in acute
psychotic disorders
Ehlis AC, Zielasek J,
Herrmann MJ, Ringel T, Jacob Ch, Fallgatter AJ
Eur Arch Psychiatry Clin Neurosci. 2005
Oct;255(5):299-307
Amoxapine as an Atypical Antipsychotic: A Comparative Study
Vs Risperidone
Rogelio Apiquian, Ana Fresan,
Rosa-Elena Ulloa, Camilo de la Fuente-Sandoval, Miguel Herrera-Estrella,
Alejandra Vazquez, Humberto Nicolini and Shitij Kapur
Neuropsychopharmacology (2005) 30, 2236-2244
Effects of Noncompetitive NMDA Receptor Blockade on Anterior
Cingulate Cerebral Blood Flow in Volunteers with Schizophrenia
Henry H Holcomb, Adrienne C Lahti,
Deborah R Medoff, Tom Cullen and Carol A Tamminga
Neuropsychopharmacology (2005) 30, 2275-2282
Occupancy of Striatal and Extrastriatal Dopamine D2/D3
Receptors by Olanzapine and Haloperidol
Robert M Kessler, Mohammad Sib
Ansari, Patrizia Riccardi, Rui Li, Karuna Jayathilake, Benoit Dawant and
Herbert Y Meltzer
Neuropsychopharmacology (2005) 30, 2283-2289
Augmentation of olanzapine
in treatment-resistant schizophrenia
Mathias Zink
J Psychiatry Neurosci 2005;30(6):409-15
Su KP, Wu PL,
Pariante CM
Psychopharmacology (Berl). 2005 Oct 21;:1-4
Dermatoglyphic
anomalies and neurocognitive deficits in sibling pairs discordant for
schizophrenia spectrum disorders
Araceli Rosa,
Manuel J. Cuesta, Víctor Peralta, Amalia Zarzuela, Fermín Serrano, Alfredo
Martínez-Larrea and Lourdes Fañanás
Psychiatry Research. Volume 137, Issue 3, 15 December 2005, Pages 215-221
Efficacy and tolerability of ziprasidone in patients with
treatment-resistant schizophrenia
Kane, John M; Khanna, Sumant; Rajadhyaksha,
Sunita; Giller, Earl
International Clinical Psychopharmacology.
21(1):21-28, January 2006
Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of
frequency, correlates and course
Eberhard, Jonas; Lindstrom, Eva; Levander,
Sten
International Clinical Psychopharmacology.
21(1):35-42, January 2006
A double-blind, controlled study of sertindole versus risperidone in the
treatment of moderate-to-severe schizophrenia
Azorin, Jean-Michel; Strub, Nathalie; Loft,
Henrik
International Clinical Psychopharmacology.
21(1):49-56, January 2006